Management of genitourinary syndrome of menopause in breast cancer survivors: An update

Figure 1 Treatment of genitourinary syndrome of menopause in women undergoing adjuvant treatment for breast cancer. ¹Dehydroepiandrosterone; ²Prasterone label includes a warning against this use in breast cancer survivors.

Figure 2 Treatment of genitourinary syndrome of menopause in women who have completed their adjuvant treatment for breast cancer. ¹Food and Drug Administration does not recommend ospemifene for women at risk or with history of breast cancer or those with known or suspected estrogen-dependent neoplasia[84]; ²Dehydroepiandrosterone; ³Prasterone label includes a warning against this use in breast cancer survivors.